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Summary
Background: Treatment for coeliac disease is a lifelong strict gluten‐free diet. 
Although guidelines recommend regular follow‐up with dietary interviews and coe‐
liac serology, these methods may be inaccurate.
Aim: To evaluate the usefulness of faecal gluten immunogenic peptides to support the 
diagnosis and to determine the adherence to the gluten‐free diet in coeliac children.
Methods: Multicentre prospective observational study including 64 coeliac children. 
Faecal gluten peptides, and tissue transglutaminase and deamidated gliadin peptide 
antibodies were analyzed at diagnosis, and 6, 12 and 24 months thereafter. Gluten 
consumption was estimated from gluten peptide levels.
Results: Most children (97%) had detectable gluten peptides at diagnosis. On a glu‐
ten‐free diet, the rate of gluten peptides increased from 13% at 6 months to 25% at 
24 months. Mean estimated gluten exposure dropped from 5543 mg/d at diagnosis 
to 144 mg/d at 6 months, then increased to 606 mg/d by 24 months. In contrast, 
deamidated gliadin peptide antibodies normalised and only 20% had elevated tissue 
transglutaminase antibody by 24 months. The elevation of tissue transglutaminase 
antibody was more prolonged in patients with detectable gluten peptides (P < 0.05). 
Nevertheless, absolute levels of tissue transglutaminase antibody had low sensitivity 
to identify patients with detectable gluten peptides (P > 0.1). Dietitian assessment 
was only moderately correlated with gluten peptide detection (κ = 0.5).
Conclusions: Faecal gluten peptides testing may guide treatment of coeliac disease 
prior to diagnosis and during the assessment diet adherence. Further studies could 
determine if early identification of gluten exposure reduces the need for expensive/
invasive investigations for non‐responsive coeliac disease. ClinicalTrials.gov Number: 
NCT02711397.
© 2019 The Authors. Alimentary Pharmacology & Therapeutics Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
Coeliac disease is an immune‐mediated disorder of the small intes‐
tine that affects ~1% of most populations.1,2 This lifelong condition 
is initiated by exposure to dietary gluten in genetically susceptible 
individuals and can affect any organ or tissue. Consequently, a vari‐
ety of gastrointestinal and extra‐intestinal symptoms are observed, 
such as abdominal pain, malabsorption, anaemia, failure to thrive, 
osteoporosis and, occasionally, lymphoma.3
A lifelong gluten‐free diet (GFD) is currently the only avail‐
able treatment for coeliac disease and has been shown to improve 
quality of life substantially, both in patients initially presenting 
with gastrointestinal symptoms and in asymptomatic patients.4 
However, adherence to the GFD is not easy because gluten is 
ubiquitous and often not explicitly listed as an ingredient in food 
products. As a result, persistent symptoms and enteropathy are 
common among coeliac patients who are trying to follow a GFD. 
Specifically, research shows that 25%‐40% of adults with coeliac 
disease have persistent enteropathy after 2 years on a GFD.5‐7 
Children are thought to recover more quickly, and data suggests 
that 5%‐19% of coeliac children on a GFD may have persistent 
enteropathy despite treatment with a GFD for at least 1 year.8‐13 
Moreover, while the experts agree strict adherence to the GFD is 
crucial for the health of coeliac patients, there are no evidence‐
based recommendations regarding the most efficient way to as‐
sess GFD adherence.14 Typically, dietary history, symptoms and 
serum antibody tests are used to assess non‐adherence. However, 
a detailed dietary history is time consuming and requires the col‐
laboration of a dietician, so in routine clinical practice, physicians 
often rely upon the patient's own subjective assessment of dietary 
adherence, or the presence of adverse symptoms to guide dieti‐
cian referral. The difficulty with this approach is that many non‐
adherent patients may be asymptomatic. In addition, if patients do 
have symptoms, these may be as a result of coexisting disorders, 
such as irritable bowel syndrome, microscopic colitis or pancre‐
atic insufficiency.15 Concerningly, although coeliac antibody tests 
are widely used for routine monitoring of coeliac patients, these 
tests were never approved for this purpose and have low sensi‐
tivity in detection of persistent mucosal lesion in coeliac patients 
on a GFD.16 Therefore, none of these methods offer an accurate 
measure of dietary adherence. Whilst duodenal biopsy is consid‐
ered the ‘gold standard’ for assessment of celiac disease activity,17 
certain associations, such as the European Society for Pediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) Coeliac 
Disease working group strongly advises against regular re‐biopsy 
in children on a GFD, due to unnecessary risks for the patient, neg‐
ative impacts on quality of life, and pointless high medical costs.18
Monoclonal antibodies capable of sensitively and specifically 
detecting gluten immunogenic peptides (GIP) have been used to 
develop assays for detecting inadvertent gluten consumption by 
measuring GIP in human samples (faeces and urine). These assays 
may be a practical method to assess dietary adherence in coeliac 
patients.19‐21 GIP are resistant to gastrointestinal digestion and ac‐
count for immunogenic reactions in T cells of patients with coeliac 
disease.22 Unlike traditional methods to monitor GFD adherence 
which only evaluate the consequences of GFD transgressions, this 
non‐invasive method enables a direct and quantitative assessment 
of gluten exposure. A recent study demonstrated the clinical use‐
fulness of GIP as a marker of GFD adherence in patients following a 
GFD for at least 1 year.20 Although it is well known that compliance 
with the GFD overall decreases on long term follow‐up, however 
strict adherence to a GFD in the first year after the diagnosis crucial 
to favour mucosal recovery. For this reason, the aim of the present 
study was to evaluate the measurement of GIP in stools as a marker 
of GFD adherence in newly diagnosed coeliac children in a prospec‐
tive multicentre clinical trial. Furthermore, this was compared to tra‐
ditional methods used to assess GFD adherence: dietitian review of 
four‐day food recrod and coeliac serology (tissue transglutaminase, 
tTG and deamidated gliadin peptide antibodies, DGP).
2  | MATERIAL S AND METHODS
2.1 | Study design
A multicentre prospective observational study of detection of GIP 
in stool in a cohort of children newly diagnosed with coeliac dis‐
ease was performed at seven Spanish secondary and tertiary refer‐
ral hospitals: Hospital Nuestra Señora de la Candelaria (Tenerife), 
Hospital Regional Carlos Haya (Málaga), Hospital Universitario y 
Politécnico La Fe (Valencia), Hospital Universitario Virgen del Rocío 
(Sevilla), Hospital Universitario Virgen de Valme (Sevilla), Instituto 
Hispalense de Pediatría (Sevilla), Hospital Universitario Río Hortega 
(Valladolid) and Hospital Sant Joan de Reus (Tarragona). There were 
four study visits at diagnosis and, 6 (from 4‐9 months), 12 (from 
10‐15 months) and 24 (from 16‐24 months) months after diagnosis. 
The first visit (diagnosis) was at the time of diagnostic endoscopy 
when patients were untreated (diet with gluten). All participants 
were instructed to follow a GFD by clinical dieticians with expertise 
in coeliac disease. Samples of faeces and blood were collected at 
each study visit and participants completed a four‐day food record 
according to the dietician instructions. The study protocol was re‐
viewed by the ethics committee at each participating hospital and 
written informed consent was obtained from the parents or legal 
guardians.
2.2 | Study population
Children (less than 18 years of age) with active coeliac disease 
were recruited at time of diagnostic endoscopy. Inclusion criteria 
were: (a) symptoms—either gastrointestinal (eg, abdominal pain, 
diarrhea, constipation, weightloss, flatulence, bloating, vomiting, 
lack of appetite) or atypical (e.g., iron deficiency anaemia, chronic 
fatigue, behavioural changes, poor growth); (b) elevated serum 
EMA IgA, tTG IgA/IgG and/or DGP IgA/IgG; (c) HLADQ2 and/or 
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HLADQ8 genotype; and, (d) small intestinal histology consistent 
with coeliac disease (Marsh II‐III). Exclusion criteria were: (a) his‐
tory of kidney, liver or severe psychiatric disease; (b) seizure disor‐
der and/or current use of anticonvulsants; (c) use of any antibiotics 
within the year prior to enrolment.
All subject data were recorded in an electronic data capture 
(EDC) system, including: age, weight, height, intestinal histology, 
symptoms, comorbiditions, clinical test results, adverse events, 
family history of coeliac disease, date of coeliac disease diag‐
nosis, adherence to GFD, and details sample collection and visit 
attendance.
2.3 | Faeces and blood collection
Subjects were instructed to collect 2‐4 g stool in a sealed con‐
tainer after recording their food intake for 4 days. Specimens were 
dropped‐off within 24 hours of collection and were kept at −20°C at 
all times until processing.
Blood samples were collected in two 3 mL vacutainer tubes with 
EDTA‐K3 anticoagulant and centrifuged at 2000 g within 30 min‐
utes of collection to obtain plasma which was stored at −80°C until 
analysis. Investigators performing stool and serum analysis were 
blinded to GFD status at the time of sample collection.
2.4 | Quantification of GIP in stool samples
Stool GIP concentration was determined by sandwich enzyme‐
linked immunosorbent assay (ELISA; iVYDAL In Vitro Diagnostics 
iVYLISA GIP Stool kit, Biomedal S.L., Seville, Spain) according to 
the manufacturer's protocol. Briefly, stool samples were mixed 
with 9 ml Universal Gluten Extraction Solution (UGES; Biomedal 
S.L., Seville, Spain) per gram of stool then incubated at 50°C for 
60 minutes with gentle agitation to release the GIP from the stool 
matrix. After extraction, samples were diluted 1:10 with dilution 
solution and ELISA was performed using the provided G12 coated 
microtiter plate, standards (50, 25, 6.25, 3.13, 1.56 ng/ml GIP) and 
positive and negative controls. Thus, results were expressed as 
μg GIP per gram faeces. Each sample was run in duplicate and at 
least two different aliquots of each sample were tested on differ‐
ent days.
The validity of this method in detecting GFD transgressions 
was determined by the analytical sensitivity (limits of detection and 
quantification 0.06 and 0.16 μg GIP per gram faeces, respectively) 
and the diagnostic sensitivity and specificity (98.5% and 100%, 
respectively).20
2.5 | Estimation of gluten consumption
A calibration factor allowed estimation of the ingestion of glu‐
ten in coeliac patients from stool measurements. Specifically, the 
equation for estimating daily gluten consumption in milligrams (y 
variable) based upon faecal GIP concentration (in micrograms per 
gram) (x variable) was determined from measured mean values 
of 6.2 and 14.9 μg GIP per gram faeces during controlled gluten 
challenges of 9 and 30 grams per day.19,20,23 Fitting to a sec‐
ond‐order polynomial going through the origin gave the relation 
y = 0.0649x2 + 1.0461x.
2.6 | Serology
The levels of tTG IgA and DGP IgA antibodies (IgG in IgA‐deficient 
patients) were determined by ELISA using the EliATM Celikey® and 
EliATM Gliadin kits, respectively, according to the manufacturer's 
protocol (Phadia, Freiburg, Germany). Measurements were per‐
formed in duplicate and the results expressed as U/ml. The manu‐
facturer recommended cut‐off of >10 U/mL was used.
2.7 | Dietary questionnaire
To assess gluten exposure, a structured food questionnaire of 27 
items was administered to record the foods consumed during the 
4 days prior to stool and blood collection. The food items were clas‐
sified into eight predefined groups: dairy (milk and cheese); com‐
plex carbohydrates (bread, cereals, pasta, rice, potato, legumes, and 
nuts); meats (red meat, fish, cold cuts, and eggs); fruits (whole or 
juiced); vegetables; fats (vegetable oils, butter, and cream); sweet‐
ened beverages (sodas, bottled juices, and energy drinks); and other 
(baked goods, candy, snacks, etc.). Images of standard portion sizes 
were included as a guideline for portion quantification. Subjects 
were asked to record the amount and type of food consumed, brand, 
time of meal, and if it was labelled as gluten‐free. They were also 
asked to note if they were aware of having consumed any gluten‐
containing foods.
2.8 | Statistical analysis
Quantitiative variables are expressed as median with interquar‐
tile range (IQR), and the categorical variables as percentages. 
Goodness‐of‐fit to normal was checked using the Shapiro‐Wilk test. 
Pearson's chi‐squared test was used for categorical variables, and 
the chi‐squared test for ordinal variables. Statistical analysis of the 
degree of concordance of the dichotomously evaluated diagnostic 
techniques was performed using Cohen's kappa index (κ), following 
the criteria of Landis and Koch24 for the qualitative interpretation of 
the strength of concordance. The Mann‐Whitney U test was used to 
compare quantitative variables in independent groups. For all cases, 
P < 0.05 was considered statistically significant. Data analysis was 
performed with SPSS 23.0 for Windows (SPSS Inc).
3  | RESULTS
The study population consisted of 64 children (21 males and 43 
females) with a median age of 4 years (IQR 1.5‐9 years; Table 1). 
Participant retention was 94% at 6 months, 78% at 12 months and 
55% at 24 months (the most common reason for loss to follow‐up 
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were: moving out of the study area, not attending follow‐up visits 
and forgetting to collect samples).
3.1 | Detection of GIP in stool
At the initial visit, before starting the GFD, during the expected glu‐
ten challenge for diagnosis, 62 (97%) patients had detectable GIP 
in the provided stool sample. After diagnosis and treatment with a 
GFD, 13 (23%) of patients had detectable levels of GIP in at least one 
visit, whereas 11 (20%) were noncompliant according to the ques‐
tionnaire. Overall, 11% of all coeliac patients were noncompliant by 
both methods, 48% were gluten free by both methods (κ = 0.5) and 
39% were discordant. In general, GFD adherence rates declined as 
the study progressed (Figure 1A,B). The rate of GIP positive stools 
was 13% at 6 months, 18% at 12 months and 25% at 24 months. 
Notably, 46% of transgressors had detectable GIP at two or more 
follow‐up visits (Figure 1C).
The rate of GIP positive stools during follow‐up increased with 
age (P = 0.041). Specifically, GIP were detected in stools from 6% of 
children with coeliac disease before 2 years of age, and in 24% and 
35% in those diagnosed at 2‐6 years and at an older age, 7‐18 years, 
respectively (Figure 2).
Eleven participants (17%) reported no classic symptoms prior 
to diagnosis with coeliac disease and instead were biopsied for 
atypical symptoms or laboratory abnormalities. The rate of di‐
etary transgressions in this group was 33% compared to 19% for 
the group diagnosed due to classical coeliac disease symptoms 
(P = 0.57).
3.2 | Estimated gluten ingestion
An estimate of gluten consumption by coeliac patients following a 
GFD was determined by measuring GIP in stool. Both the mean and 
median values for each visit are reported due to the non‐normal distri‐
bution of gluten ingestion (Table 2). At diagnosis, estimated daily glu‐
ten consumption was 5543 mg (mean) with a 95% CI [4345‐6741 mg] 
and 3882 mg (median). During transition to a GFD, we found 342 mg 
gluten (mean), 95% CI [67‐616 mg] and 104 mg (median) in samples 
tested. There was a trend toward increased gluten consumption dur‐
ing the follow‐up period. After diagnosis, estimated gluten exposure 
was (mean/median) 144/99 mg/d at 6 months, 452/105 mg/d at 
12 months, and 606/117 mg/d at 24 months.
3.3 | Correlation between faecal GIP and 
serum antibodies
Serum tTG and DGP antibodies levels declined during follow‐up 
(Figure 3A). For tTG antibody, 48% were positive at the 6 months 
visit, 34% at 12 months and 20% at 24 months. For DGP antibody, 
positive results were obtained in 11% at 6 months, 5% at 12 months 
and 0% at 24 months. In contrast, rates of GIP positive stools showed 
an upward trend during the follow‐up period and were highest at the 
last visit (Figure 3B).
Considering the absolute values for both tTG and DGP antibod‐
ies at each visit, we did not find concordance for GIP, with very low 
kappa values, far from statistical significance (P > 0.1). Nor was there 
statistical concordance when using dichotomous terms that is, pos‐
itive when GIP were detected at least one follow‐up visit (6, 12, or 
24 months), and negative when GIP were not detected during fol‐
low‐up (Table 3). The kappa values were very low, far from statistical 
significance (P > 0.1) in all cases.
Figure 3 displays the absolute reduction in the tTG antibody 
titer after 6 months (Figure 3A) and 12 months (Figure 3B) of GFD 
therapy. We also found a substantial, significant, reduction in the 
tTG antibody with respect to the basal (diagnosis) levels; this trend 
was stronger in the group of patients adhering to the GFD, as 
demonstrated by the negative GIP, with reductions of 103 U/mL 
(IQR 50‐122) vs 28 U/mL (IQR 12‐63) in the positive GIP patients 
after 6 months of GFD (P = 0.028) (Figure 4A). This differential 
kinetic behaviour of the tTG antibody in the two groups was also 
observed at 12 months of treatment: 116 U/mL (IQR 61‐127) in 
adherents vs 48 U/mL (IQR 31‐101) (P = 0.038) in non‐adherents 
(Figure 4B).
4  | DISCUSSION
In this study of children with coeliac disease, the rate of GIP detec‐
tion in stool dropped dramatically from 97% at diagnosis to 13% after 
6 months of GFD. This high level of adherence after a GFD was not 
maintained on follow‐up. Some children may relax the GFD as evi‐
denced by an increasing rate of GIP detection with time. We found 
that 46% of non‐adherent participants had two or more GIP posi‐
tive stools on a GFD. This suggests a behavioural pattern involving 
repeated or chronic gluten exposure rather than infrequent episodic 
exposures. As expected, the stool GIP concentration in many non‐ad‐
herent patients was low, close to the limit of quantification (0.16 μg 
GIP per gram faeces). Nevertheless, this level of exposure is likely 
significant as children who had detectable GIP in their stool at any 
time after diagnosis had a more prolonged elevation of their serum 
tTG antibody than those with all stools being negative while trying 
TA B L E  1   Characteristics of 64 patients with celiac disease 
enrolled in the study
Characteristic Patients, n (%)
Sex
Male 21 (33%)
Female 43 (67%)
Age (y)
<2 16 (25%)
2‐6 21 (33%)
7‐18 27 (42%)
Median age 4
Interquartile range (P25‐P75) 1.5‐9
1488  |     COMINO et al.
to follow a GFD. Furthermore, some patients had faecal GIP levels 
similar to those of healthy controls on a gluten containing diet.19,20
Investigation of factors underlying gluten exposure was be‐
yond the scope of the current study; however, it must not be 
assumed that gluten ingestion was intentional. Although all fami‐
lies received GFD education from a dietician, it cannot be expected 
that they are implementing a GFD correctly. Similar to our previ‐
ous studies,20 children younger than two years old had the highest 
and most sustained adherence to GFD using objective measures. 
This group, beside having overall a more controlled diet, is highly 
dependent on their parent or guardian to be fed; therefore, strict 
control over the diet may be easier to achieve compared with older 
children (7‐18 years old). Thus these differences may reflect the 
increasing autonomy of the patient regarding dietary decisions. 
Adolescence is a developmental phase characterised by rebel‐
lion and others have found that teenagers may be particularly 
susceptible to the burden of a GFD related to stigmatization and 
are more likely intentionally non‐adherent in such settings.25‐27 
Alternatively, older children and adolescents are also more likely 
to eat outside the home (eg, at school, at a friends’ home) thus 
having food prepared by persons not always well‐informed about 
the GFD requirements. The increased rate of GIP detection with 
age may simply reflect that these behaviours are inherently more 
“risky” with regards to gluten exposure. Among adults, symptom‐
atic suspected gluten reactions are most commonly associated 
with eating at restaurants.28 Alternatively, it may be that the habit 
of GFD adherence, when established in early childhood, is main‐
tained through adolescence and adulthood. This would suggest 
that diagnosing patients with coeliac disease as early in life as pos‐
sible should be a priority to avoid social problems and physical and 
psychological deterioration.29
F I G U R E  1   Concentration of gluten immunogenic peptides (GIP) in stools of patients with newly diagnosed coeliac disease during 
monitoring of the gluten‐free diet. (A) Levels of faecal GIP at the basal and follow‐up visits (basal, 6, 12 and 24 mo). (B) Levels of faecal GIP 
at 6, 12 and 24 mo. (C) Levels of GIP in transgressing patients in the different follow‐up visits (log scale). GIP, gluten immunogenic peptides; 
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The initial symptomatic response to a GFD tends to be rela‐
tively rapid, occurring within days to weeks, especially in patients 
presenting with classical symptoms. Conversely, gluten expo‐
sure on a GFD may not evoke symptoms.28,30 We found the rate 
of GIP positive stools increased with time since diagnosis, which 
may reflect a tendency to relax GFD adherence over time as pa‐
tients identify that they may tolerate some gluten without symp‐
toms and adjust their diet accordingly. The estimated gluten intake 
of patients on a GFD (median 0.104 grams per day) was be more 
than 30‐fold less than the typical amount used in gluten challenge 
(3‐10 g/d).30 Perhaps, ingestion of 0.1‐0.5 g gluten does not gener‐
ate symptoms in a significant proportion of non‐adherent patients. 
A safe threshold for gluten consumption by persons with coeliac 
disease has not been established; however, it is accepted that glu‐
ten tolerance varies widely.31,32 Consistent with this notion, those 
who were symptomatic at diagnosis were less likely than those who 
were asymptomatic to have detectable GIP in the stool. Other in‐
vestigators have also identified a desire to avoid symptoms as a 
motivation for adhering strictly to a GFD.33‐35
Our finding that most children were able to substantially reduce 
their gluten ingestion within 6 months has implications for the defi‐
nition of “non‐responsive coeliac disease”. A categorization rather 
than a diagnosis, non‐responsive coeliac disease has been defined 
as “persistent symptoms, signs, or laboratory abnormalities typi‐
cal of coeliac disease despite 6‐12 months of dietary gluten avoid‐
ance”.36 The duration of gluten avoidance required to be considered 
TA B L E  2   Estimated gluten consumption based upon GIP measured in stoola 
GFD duration (mo) n
GIP concentration (μg/g stool) Estimated gluten consumption (mg/d)
Mean Median IQR Mean Median IQR
0 (diagnosis) 64 3.82 3.11 0.60‐7.60 5543 3882 691‐11 699
6 54 0.14 0.09 0.05‐0.14 144 99 49‐149
12 39 0.34 0.10 0.05‐0.15 452 105 52‐160
24 24 0.43 0.11 0.06‐0.18 606 117 58‐190
GFD, gluten‐free diet; GIP, gluten immunogenic peptides.
aConversion factor x = GIP (μg/g stool) to y = gluten daily consumption (mg) is y = 0.0649x2 + 1.0461x. 
F I G U R E  3   Evolution of GIP, tTG and DGP antibodies in patients with newly diagnosed coeliac disease. (A) tTG and DGP antibody levels 
vs time. (B) Percentage of dietary transgressions according GIP, tTG and DGP antibodies during the study period. DGP, deamidated gliadin 
peptide antibody; tTG, tissue transglutaminase antibody; GFD, gluten‐free diet; GIP, gluten immunogenic peptides. The cut‐off >10 U/mL
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TA B L E  3   Evolution of the GFD according to the comparative GIP and coeliac disease serologies
Time of GFD Comparison GIP vs λc 95% CI λc Criterios azzimonti Kappa (P)
Evolutionary tTG IgA 57.4 42.3‐68.4 No 0.107 (0.342)
DGP IgA 65.6 52.9‐78.0 No 0.103 (0.423)
CI, confidence interval; DGP, deamidated gliadin peptide antibody; GFD, gluten‐free diet; GIP, gluten immunogenic peptides; tTG, tissue transglu‐
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non‐responsive has been controversial, with some groups requiring 
at least 12 months of gluten restriction before considering patients 
non‐reponsive37,38 and others suggesting that inadequate symptom‐
atic response after 6 months on a GFD should prompt investigation 
for etiologies other than coeliac disease.39 Our data suggest that 
6 months may be a reasonable definition as most children substan‐
tially reduced their gluten intake within this timeframe. Regardless 
of the definition, gluten ingestion (either intentional or inadvertent) 
is consistently found to be the leading cause of non‐responsive co‐
eliac disease.38,39 Testing for GIP in stool may be a useful tool in 
the evaluation of non‐responsive coeliac disease. Identification of 
ongoing gluten exposure may guide treatment and obviate the need 
for expensive and invasive investigations.
Our findings also help to clarify the interpretation of coeliac 
serology tests after a diagnosis of coeliac disease is established. 
Although widely used to monitor patients on a GFD and highly 
specific for persistent villous atrophy on a GFD, the low sensitivity 
of serum tTG, EMA and DGP antibodies tests renders a negative 
test substantially less informative.16,40 We found that those with 
detectable levels of GIP in stool had a more prolonged elevation 
and a more gradual fall in tTG antibody than those whose stools 
tested negative. However, in absolute and evolutive (dichotomous) 
terms, no concordance is observed between the tTG antibody and 
GIP levels.
Strengths of our study include the use of a robust and objec‐
tive measure of gluten exposure in a population of children who all 
received formal GFD education and who were followed prospec‐
tively from diagnosis. Contemporaneous food record completion 
and stool and serum collection allowed for accurate correlation of 
serology with faecal GIP detection. Loss to follow‐up is a limitation 
of our study that does complicate interpretation of increased gluten 
exposure.
In conclusion, serial analysis of faecal GIP allowed not only the 
first direct confirmation of gluten intake days before coeliac disease 
diagnosis, but also documentation of a substantial decrease in gluten 
consumption after diagnosis of coeliac disease and instruction in fol‐
lowing a GFD. The introduction of GIP as an assessment tool of GFD 
adherence may help to ascertain dietary compliance and reduce the 
need for additional invasive investigations on follow‐up.
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